Monday, November 17, 2014 10:21:34 AM
-- A tremendous, respectful, and mutually supportive working arrangement with NWBO. Linda knows how to work with researchers. (My words).
-- UCLA has done little work to date with Direct. Looking forward to it and preparing a Protocol for a new NWBO sponsored trial (possibly with the cosponsorship of the adjuvant maker) with adjuvants.
-- Made it clear that NWBO owns the commercialization of DCVax.
-- Results for Phase 1/2 DCVax-L trial are due shortly. No hint of him knowing the results. He is a pro researcher. Everything is in the data.
-- The 5000 stored tumors and most stored tumors are frozen for research purposes. These are not lysate capable. Patient must ordinarily request the saving of tissue.
--BMY researchers were aware and complementary toward NWBO's trial standards. Called it, "certainty one of the best." Referring to its structural integrity.
-- Several attendees had doubts about the Novo "helmet" trial getting stopped for 3 months of efficacy. They all questioned the data.
--Immunotherapy was at the forefront of discussion at SNOW. NWBIO has the research communities attention. Everyone waiting for results, end of 2015. Researchers here are only interested in complete data. When I mentioned 149 events and the first interim review. Several researchers, including Prins, just looked at me. They don't think that way. He did not realize that a review was being done at 149 events and did not see the importance that we place on the event. (Only the companies do.)
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM